| Literature DB >> 30634617 |
Min-Cheol Kang1,2, Yuling Ding3, Hyun-Soo Kim4, You-Jin Jeon5, Seung-Hong Lee6.
Abstract
The purpose of this study was to investigate the antiobesity effect and the mechanism of action of diphlorethohydroxycarmalol (DPHC) isolated from Ishige okamurae in 3T3-L1 cells. The antiobesity effects were examined by evaluating intracellular fat accumulation in Oil Red O-stained adipocytes. Based on the results, DPHC dose-dependently inhibited the lipid accumulation in 3T3-L1 adipocytes. DPHC significantly inhibited adipocyte-specific proteins such as SREBP-1c, PPARγ, C/EBP α, and adiponectin, as well as adipogenic enzymes, including perilipin, FAS, FABP4, and leptin in adipocytes. These results indicated that DPHC primarily acts by regulating adipogenic-specific proteins through inhibiting fat accumulation and fatty acid synthesis in adipocytes. DPHC treatment significantly increased both AMPK and ACC phosphorylation in adipocytes. These results indicate that DPHC inhibits the fat accumulation by activating AMPK and ACC in 3T3-L1 cells. Taken together, these results suggest that DPHC can be used as a potential therapeutic agent against obesity.Entities:
Keywords: adipocytes; adipogenesis; antiobesity; diphlorethohydroxycarmalol (DPHC)
Mesh:
Substances:
Year: 2019 PMID: 30634617 PMCID: PMC6356311 DOI: 10.3390/md17010044
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The effect of diphlorethohydroxycarmalol (DPHC) on the cell viability of 3T3-L1 preadipocytes treated for 48 h (A). DPHC inhibits intracellular lipid accumulation in 3T3-L1 adipocytes. Lipid accumulation was determined by Oil Red O staining (B). Scale bars for B is 50 μm. Data are expressed as the mean of three independent experiments, and the error bars represent the mean ± SE. Significant differences from the control group were identified at * p < 0.05.
Figure 2The effect of DPHC treatment on adipogenic-specific protein levels in 3T3-L1 adipocytes. The 3T3-L1 preadipocytes were incubated in a differentiation medium with or without the indicated concentrations of DPHC for eight days (from day 0 to day 8). The expression of sterol regulatory element-binding protein 1c (SREBP-1c), peroxisome proliferator-activated receptor-γ (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), and adiponectin were assessed by Western blotting (A). The expression of perilipin, fatty acid synthase (FAS), fatty acid binding protein (FABP4), and leptin were assessed by Western blotting (B). Immunoblot figures are representative of three independent experiments, and each value is expressed as the mean ± SE of three determinations. Significant differences from the control group were identified at * p < 0.05.
Figure 3DPHC suppresses the activation of p-AMPKα and p-ACC in 3T3-L1 preadipocytes. 3T3-L1 preadipocytes were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with or without different concentrations of DPHC for eight days (from day 0 to day 8) until their differentiation into adipocytes. Immunoblot figures are representative of three independent experiments, and each value is expressed as the mean ± SE of three determinations. Significant differences from the control group were identified at * p < 0.05.
Figure 4Chemical structure of diphlorethohydroxycarmalol (DPHC).